United States · FDA National Drug Code directory
OXBRYTA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 72786-111_e27a3e07-438e-49d3-aae3-095e9379c7b4
- Product NDC
- 72786-111
- Form
- TABLET, FOR SUSPENSION
- Composition / generic term
- Voxelotor
- Labeler
- Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20211217
- Source listing expiry
- 20261231
Source-listed ingredients
- VOXELOTOR — 300 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 60 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-02) · 72786-111-02
- 90 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-03) · 72786-111-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →